Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13).

Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13).

BACKGROUND: There are few data on plasma and intracellular pharmacokinetics (PK) of once-daily (q24h) nucleoside analogues in HIV-infected children. METHODS: Children aged 2-13 years receiving combination treatment containing lamivudine (3TC) (4 mg/kg) and/or abacavir (ABC) (8 mg/kg) twice daily (q1...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron:	Bergshoeff, A, Burger, D, Verweij, C, Farrelly, L, Flynn, J, Le Prevost, M, Walker, S, Novelli, V, Lyall, H, Khoo, S, Gibb, D
Fformat:	Journal article
Iaith:	English
Cyhoeddwyd:	2005

Eitemau Tebyg

Adherence and acceptability of once daily Lamivudine and abacavir in human immunodeficiency virus type-1 infected children.
gan: LePrevost, M, et al.
Cyhoeddwyd: (2006)

Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial.
gan: Musiime, V, et al.
Cyhoeddwyd: (2010)

Once- versus twice-daily abacavir and lamivudine in African children: the randomised controlled ARROW Trial
gan: Musiime, V, et al.
Cyhoeddwyd: (2016)

Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial).
gan: Gibb, D, et al.
Cyhoeddwyd: (2002)

Plasma pharmacokinetics of once-daily abacavir- and lamivudine-containing regimens and week 96 efficacy in HIV-infected Thai children
gan: Torsak Bunupuradah, et al.
Cyhoeddwyd: (2015-07-01)

Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children.
gan: Green, H, et al.
Cyhoeddwyd: (2007)

A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study)
gan: McClernon Daniel, et al.
Cyhoeddwyd: (2009-04-01)

Interactions of Tenofovir, Lamivudine, Abacavir and Didanosine in Primary Human Cells
gan: Saye H. Khoo, et al.
Cyhoeddwyd: (2011-06-01)

Abacavir/lamivudine combination in the treatment of HIV: a review
gan: Geetha Sivasubramanian, et al.
Cyhoeddwyd: (2010-02-01)

Population Pharmacokinetic Modeling of Abacavir/Dolutegravir/Lamivudine to Support a Fixed-Dose Combination in Children with HIV-1
gan: Hardik Chandasana, et al.
Cyhoeddwyd: (2024-07-01)

Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial.
gan: David A Wohl, et al.
Cyhoeddwyd: (2014-01-01)

Once and Twice
gan: Richard S. Kayne
Cyhoeddwyd: (2015-05-01)

Correction: Simplification to Abacavir/Lamivudine + Atazanavir Maintains Viral Suppression and Improves Bone and Renal Biomarkers in ASSURE, a Randomized, Open Label, Non-Inferiority Trial
Cyhoeddwyd: (2014-01-01)

Correction: Simplification to Abacavir/Lamivudine + Atazanavir Maintains Viral Suppression and Improves Bone and Renal Biomarkers in ASSURE, a Randomized, Open Label, Non-Inferiority Trial.
Cyhoeddwyd: (2014-01-01)

Simultaneous Determination of Lamivudine, Zidovudine and Abacavir in Tablet Dosage Forms by RP HPLC Method
gan: D. Anantha Kumar, et al.
Cyhoeddwyd: (2010-01-01)

Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir.
gan: Ndembi, N, et al.
Cyhoeddwyd: (2010)

Measure Twice, Cut Once∗
gan: David A. D’Alessandro, MD, et al.
Cyhoeddwyd: (2021-05-01)

Efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 24 weeks
gan: Julián Olalla, et al.
Cyhoeddwyd: (2018-10-01)

Measure twice, cut once /
gan: 319488 Tolpin, Jim
Cyhoeddwyd: (1996)

Twist it once, twist it twice
gan: Anna Wiehl
Cyhoeddwyd: (2022-02-01)

Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets.
gan: L'homme, R, et al.
Cyhoeddwyd: (2008)

Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study.
gan: Wolbers, M, et al.
Cyhoeddwyd: (2007)

Combination dolutegravir–abacavir–lamivudine in the management of HIV/AIDS: clinical utility and patient considerations
gan: Cruciani M, et al.
Cyhoeddwyd: (2015-02-01)

Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.
gan: Munderi, P, et al.
Cyhoeddwyd: (2010)

Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany
gan: Wolf E, et al.
Cyhoeddwyd: (2010-04-01)

Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain
gan: Santiago Moreno Guillen, et al.
Cyhoeddwyd: (2017-09-01)

Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudine.
gan: Allison Martin, et al.
Cyhoeddwyd: (2011-01-01)

Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.
gan: Hila Haskelberg, et al.
Cyhoeddwyd: (2012-01-01)

Bioequivalence study of abacavir/lamivudine (600/300-mg) tablets in healthy Thai volunteers under fasting conditions
gan: Ekawan Yoosakul, et al.
Cyhoeddwyd: (2016-02-01)

Pharmacokinetic Variability of Amikacin After Once-Daily and Twice-Daily Dosing Regimen in Full-Term Neonates
gan: Katarina Vučićević, et al.
Cyhoeddwyd: (2014-01-01)

Pharmacokinetics and safety after once and twice a day doses of meclizine hydrochloride administered to children with achondroplasia.
gan: Hiroshi Kitoh, et al.
Cyhoeddwyd: (2020-01-01)

An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.
gan: Josep M Llibre, et al.
Cyhoeddwyd: (2016-01-01)

Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study.
gan: Jesús Troya, et al.
Cyhoeddwyd: (2018-01-01)

Hip structural parameters over 96 weeks in HIV-infected adults switching treatment to tenofovir-emtricitabine or abacavir-lamivudine.
gan: Hila Haskelberg, et al.
Cyhoeddwyd: (2014-01-01)

Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load.
gan: Nadia Galizzi, et al.
Cyhoeddwyd: (2018-01-01)

Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications
gan: Shen J, et al.
Cyhoeddwyd: (2017-09-01)

HLA alleles association with changes in bone mineral density in HIV-1-infected adults changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.
gan: Hila Haskelberg, et al.
Cyhoeddwyd: (2014-01-01)

Left Sided Appendicitis: Once Burned Twice Shy
gan: Christos Kaselas, et al.
Cyhoeddwyd: (2016-02-01)

Safety and effectiveness of switching to abacavir/lamivudine plus rilpivirine for maintenance therapy in virologically suppressed HIV-1 individuals in Singapore (SEALS)
gan: Lim, Z. C., et al.
Cyhoeddwyd: (2021)

Efficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-naïve HIV-1 infected adults
gan: Ho, Sharlene, et al.
Cyhoeddwyd: (2021)